SCHEMBL29991127

SCHEMBL29991127

CSc1ncc2cc(C(F)F)c(=O)n(C(C)C)c2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.37
TTK P33981 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
CCND1 P24385 12/20 0.34
CCNE1 P24864 11/20 0.34
CDK2 P24941 11/20 0.34
CDK6 Q00534 11/20 0.34
CDK4 P11802 2/20 0.32
CCND3 P30281 2/20 0.32
CCND2 P30279 1/20 0.32
MAPK8 P45983 1/20 0.31
MAPK9 P45984 1/20 0.31
MAPK10 P53779 1/20 0.31
CCNT1 O60563 1/20 0.31
CCNE2 O96020 1/20 0.31
RB1 P06400 1/20 0.31
CDK1 P06493 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK9 P50750 1/20 0.31
PIK3CA P42336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25123909 1.00 PIM1 (0.37) PIM1TTKPIM2CCND1CCNE1
SCHEMBL5061885 0.81 PIM1 (0.38) PIM1TTKPIM2CCND1CDK2
SCHEMBL27362189 0.81 KMT2A (0.40) PIM1TTKPIM2CCND1CDK4
SCHEMBL29355878 0.81 PIM1 (0.38) PIM1TTKPIM2CCND1CDK2
SCHEMBL31637504 0.81 KMT2A (0.40) PIM1TTKPIM2CCND1CDK4
SCHEMBL30872552 0.79 CCND1 (0.39) CCND1CCNE1CDK2CDK6CDK4
SCHEMBL25123908 0.79 CCND1 (0.39) CCND1CCNE1CDK2CDK6CDK4
SCHEMBL31532061 0.78 PIM1 (0.39) PIM1TTKPIM2CCND1CDK4
SCHEMBL25123906 0.78 PIM1 (0.35) PIM1TTKPIM2CCND1CDK4
SCHEMBL29991085 0.78 PIM1 (0.35) PIM1TTKPIM2CCND1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572755-A2 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 EP disclosed
EP-4573094-A2 CDK2 INHIBITORS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 EP disclosed
EP-4334307-A1 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 EP disclosed
WO-2024039901-A2 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-02-22 WO disclosed
WO-2024039903-A2 CDK2 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-02-22 WO disclosed
WO-2022236058-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed